Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA’s Plaisier: GMP Oversight Must Shift To Outcomes Model

Executive Summary

In an interview with “The Pink Sheet,” the Office of Regulatory Affairs chief says she wants to chart her office’s activities based on their effect on public health instead of simply counting outputs like the number of inspections or 483s.

Advertisement

Related Content

FDA GMP Quality Metrics Will Be Industry’s ‘SAT Score’
FDA GMP “Surveillance” Will Link Quality, Compliance Information To Inspections
GMP Carrots For Quality: FDA Considers Incentives To Adopt Quality Systems

Topics

Advertisement
UsernamePublicRestriction

Register

PS056291

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel